Literature DB >> 35373055

Are the Protective Effects of SGLT2 Inhibitors a "Class-Effect" or Are There Differences between Agents?

Darren W Schmidt1, Christos Argyropoulos1, Namita Singh1.   

Abstract

Entities:  

Keywords:  SGLT2 inhibitors; chronic kidney disease; class effects; clinical trials; heart failure; sodium glucose cotransporter two inhibitors

Mesh：

Substances：

Year:  2021        PMID： 35373055      PMCID： PMC8791337          DOI： 10.34067/KID.0000622021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  11 in total

1.  Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective.

Authors:  Thomas Papoian; Haw-Jyh Chiu; Ikram Elayan; Gowraganahalli Jagadeesh; Imran Khan; Adebayo A Laniyonu; Cindy Xinguang Li; Muriel Saulnier; Natalie Simpson; Baichun Yang
Journal:  Nat Rev Drug Discov       Date:  2015-03-20       Impact factor: 84.694

2.  Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption.

Authors:  V Vallon; K Richter; R C Blantz; S Thomson; H Osswald
Journal:  J Am Soc Nephrol       Date:  1999-12       Impact factor: 10.121

3.  Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.

Authors:  Chintan N Koyani; Ioanna Plastira; Harald Sourij; Seth Hallström; Albrecht Schmidt; Peter P Rainer; Heiko Bugger; Saša Frank; Ernst Malle; Dirk von Lewinski
Journal:  Pharmacol Res       Date:  2020-05-17       Impact factor: 7.658

Review 4.  Pharmacological aspects of the safety of gliflozins.

Authors:  Jean-Luc Faillie
Journal:  Pharmacol Res       Date:  2016-07-05       Impact factor: 7.658

Review 5.  Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

Authors:  René Santer; Joaquim Calado
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-05       Impact factor: 8.237

6.  Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.

Authors:  Volker Vallon; Michael Rose; Maria Gerasimova; Joseph Satriano; Kenneth A Platt; Hermann Koepsell; Robyn Cunard; Kumar Sharma; Scott C Thomson; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2012-11-14

7.  The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

Authors:  Y Kanai; W S Lee; G You; D Brown; M A Hediger
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

8.  Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.

Authors:  L Rossetti; D Smith; G I Shulman; D Papachristou; R A DeFronzo
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

Review 9.  The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.

Authors:  Michael E Johansen; Christos Argyropoulos
Journal:  Clin Cardiol       Date:  2020-11-09       Impact factor: 2.882

10.  The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.

Authors:  Simon A Hawley; Rebecca J Ford; Brennan K Smith; Graeme J Gowans; Sarah J Mancini; Ryan D Pitt; Emily A Day; Ian P Salt; Gregory R Steinberg; D Grahame Hardie
Journal:  Diabetes       Date:  2016-07-05       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.